ADC Therapeutics SA — Director's Dealing 2024

Jan 3, 2024

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ADC Therapeutics SA (ADCT)
CIK: 0001771910
Period of Report: 2024-01-02

Reporting Person: Monges Viviane (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	68064	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$27.53	2031-02-01	Common Shares (21190)		Direct
Stock Options (Right to Buy)	$28.70	2031-03-22	Common Shares (9747)		Direct

Footnotes

F1: Includes 20,000 Common Shares to be delivered in settlement of a restricted share unit award ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Shares. The RSUs were granted on June 14, 2023 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

F2: This option vests over four years from February 1, 2021, with 1/4 vesting on the first anniversary of such date, and the remainder vesting monthly in 36 equal installments, subject to continued service through each such vesting date.

F3: This option vests over four years from March 22, 2021, with 1/4 vesting on the first anniversary of such date, and the remainder vesting monthly in 36 equal installments, subject to continued service through each such vesting date.